Managing proliferative diabetic retinopathy in a patient with vitreous hemorrhage: a case report
DOI:
https://doi.org/10.31288/oftalmolzh202235457Keywords:
proliferative diabetic retinopathy, neovascularization, intravitreal injection, ant-VEGF agentsAbstract
We report a case of successful treatment of a 35-year-old patient diagnosed with severe type 1 diabetes mellitus with moderate glycemic control, bilateral proliferative diabetic retinopathy and total vitreous hemorrhage in the right eye. At baseline, there was optical coherence tomography angiography and fundus photography evidence of significant neovascularization of the optic nerve and peripapillary retina along the vessels. Although Ukrainian guidelines on the use of aflibercept do not mention retinal neovascularization in diabetic retinopathy in the absence of diabetic macular edema as an indication for the use of aflibercept, we relied on the experience of foreign colleagues and the eye without hemorrhage was treated with five monthly loading injections of intreavitreal aflibercept 0.05 ml, and, after the first year, treatment was continued according to a “treat and extend” strategy. The case reported demonstrated that intravitreal aflibercept in combination with panretinal laser photocoagulation is effective for regression of neovascularization and prevention of recurrent vitreous hemorrhage.
References
1.Abdulaeva EA, Minkhuzina EL, Kuskov AN. [Anti-VEGF therapy for proliferative diabetic retinopathy: translating research evidence into clinical practice]. Russian Journal of Clinical Ophthalmology. 2020;20(2):97-103. https://doi.org/10.32364/2311-7729-2020-20-2-97-103
2.Demidova TYu, Trakhtenberg YuA. [Current approaches to the management of diabetic retinopathy]. Diabetes mellitus. 2014;17(3):122-8. Russian. https://doi.org/10.14341/DM20143122-128
3.Bikbov MM, Fayzrakhmanov RR, Zaynullin RM, et al. [Macular edema as a manifestation of diabetic retinopathy]. Diabetes mellitus. 2017;20(4):263-9. Russian. https://doi.org/10.14341/DM8328
4.Lytvynenko SS. [Vitreous hemorrhage after surgical treatment of diabetic retinopathy in patients with type 2 diabetes]. 2021;9(3):15-21.
5.Seidinova ASh, Ishigov IA, Seidinova ASh, et al. [Incidence of retinopathy in diabetic patients based on the data from the Diabetes Research Center]. Vestnik Kaz NMU. 2017;1:328-30.
6.Alagorie AR, Velaga S, Nittala MG, Yu HJ, Wykoff CC, Sadda SR. Effect of Aflibercept on Diabetic Retinopathy Severity and Visual Function in the RECOVERY Study for Proliferative Diabetic Retinopathy. Ophthalmol Retina. 2021 May;5(5):409-19. https://doi.org/10.1016/j.oret.2020.08.018
7.Brooks HL Jr, Caballero S Jr, Newell CK, et al. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol. 2004 Dec;122(12):1801-7. https://doi.org/10.1001/archopht.122.12.1801
8.Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018 Apr;138:271-81. https://doi.org/10.1016/j.diabres.2018.02.023
9.Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI study: phase 2 primary results of VEGF trap-eye in patients with diabetic macular edema. Ophthalmology. 2011 Sep;118(9):1819-26. https://doi.org/10.1016/j.ophtha.2011.02.018
10.Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan;41(Suppl 1):S105-S118. doi: 10.2337/dc18-S010. https://doi.org/10.2337/dc18-S010
11.Grzybowski A, Told R, Sacu S, et al. Update on Intravitreal injections: Euretina expert consensus recommendations. Ophthalmologica. 2018;239(4):181-193. https://doi.org/10.1159/000486145
12.Heidemann C, Paprott R, Stühmann LM, et al. Perceived diabetes risk and related determinants in individuals with high actual diabetes risk: results from a nationwide population-based survey. BMJ Open Diabetes Res Care. 2019. 7(1). e000680. https://doi.org/10.1136/bmjdrc-2019-000680
13.Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237:185-222. https://doi.org/10.1159/000458539
14.Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc. 2012 Jan;87(1):77-88. https://doi.org/10.1016/j.mayocp.2011.10.001
15.Taskintuna I, Elsayed ME, Taskintuna K, et al. Comparison of outcomes of four different treatment modalities for diabetic vitreous haemorrhage. Sci Rep. 2020 Feb 28;10(1):3674. https://doi.org/10.1038/s41598-020-60378-8
16.Yanoff M, Duker JS. Vitrectomy. In: Ophthalmology. 3rd ed. St Louis, MO: Mosby Elsevier;1999. p.533. https://doi.org/10.1097/00006982-199903000-00022
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 О. Б. Кощинець, Р. Л. Вадюк
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
